These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15583090)

  • 21. ACE inhibitor reduces cardiovascular events by 22%.
    Indian J Med Sci; 2000 Mar; 54(3):112-4. PubMed ID: 11227615
    [No Abstract]   [Full Text] [Related]  

  • 22. On transparency, responsibility, and accountability.
    Paul M
    Clin Microbiol Infect; 2009 Dec; 15(12):1100-2. PubMed ID: 19929974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sibrafiban. RO 483657, RO 483657-000, Xubix.
    Drugs R D; 1999 May; 1(5):387-9. PubMed ID: 10566072
    [No Abstract]   [Full Text] [Related]  

  • 25. StatBite: Key findings from the "Impact on clinical research of European legislation" report.
    J Natl Cancer Inst; 2010 Mar; 102(5):293. PubMed ID: 20173122
    [No Abstract]   [Full Text] [Related]  

  • 26. [The history of the SET-UP study (or how difficult is neutrality in clinical research)].
    Tavazzi L; Maggioni AP
    Ital Heart J Suppl; 2000 Apr; 1(4):582-3. PubMed ID: 10832152
    [No Abstract]   [Full Text] [Related]  

  • 27. Platelet function monitoring in patients with coronary artery disease.
    Gurbel PA; Becker RC; Mann KG; Steinhubl SR; Michelson AD
    J Am Coll Cardiol; 2007 Nov; 50(19):1822-34. PubMed ID: 17980247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
    Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
    Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
    [No Abstract]   [Full Text] [Related]  

  • 29. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events.
    Rinaldi MJ; Kirtane AJ; Piana RN; Caputo RP; Gordon PC; Lopez JJ; Dauerman HL; Ryan TJ; Kiernan FJ; Cutlip DE; Ho KK; Gibson CM; Murphy SA; Cohen DJ
    Am Heart J; 2008 Apr; 155(4):654-60. PubMed ID: 18371472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sham surgery and genuine standards of care: can the two be reconciled?
    London AJ; Kadane JB
    Am J Bioeth; 2003; 3(4):61-4. PubMed ID: 14744339
    [No Abstract]   [Full Text] [Related]  

  • 32. [Standard pharmacological therapy associated with percutaneous coronary interventions in patients with stable angina].
    Karcz M; Ruzyłło W
    Kardiol Pol; 2004 Nov; 61(11):480-2. PubMed ID: 15883598
    [No Abstract]   [Full Text] [Related]  

  • 33. [Antiplatelet agents--problem for cardiac surgeon].
    Bochenek A; Wilczyński M
    Kardiol Pol; 2006 Nov; 64(11):1329-31. PubMed ID: 17165174
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One size does not fit all: toward "upstream ethics"?
    Ozdemir V; Knoppers BM
    Am J Bioeth; 2010 Jun; 10(6):42-4. PubMed ID: 20526970
    [No Abstract]   [Full Text] [Related]  

  • 36. Aspirin + clopidogrel therapy: how does your care compare to the evidence?
    Simmons BB; Salzman BE
    J Fam Pract; 2008 Jan; 57(1):26-32. PubMed ID: 18171566
    [No Abstract]   [Full Text] [Related]  

  • 37. Postmenopausal hormone use in women with acute coronary syndromes.
    Parsons E; Newby LK; Bhapkar MV; Alexander KP; White HD; Shah SH; Bushnell CD; Califf RM;
    J Womens Health (Larchmt); 2004 Oct; 13(8):863-71. PubMed ID: 15671702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
    Cohen M
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Tricoci P; Newby LK
    Cardiol Rev; 2008; 16(2):89-94. PubMed ID: 18281911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous coronary intervention versus thrombolysis: the definite management of st elevation myocardial infarction.
    Martinez-Ojeda J; Martinez-Toro J
    Bol Asoc Med P R; 2005; 97(4):308-14. PubMed ID: 16599071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.